SAM.gov36C26026Q0807
Open
Long -Term Specialized Reference Laboratory for Measurable Residual Disease (MRD) detection in hematologic malignancies - Base Plus 4 9/1/26-8/31/31
- Response deadline
- Jul 10, 2026 Closed
- Date posted
- Jul 2, 2026
- Source
- Open notice
Description
The VA Portland Healthcare System (VHAPORHCS) Pathology & Laboratory Medicine Service Department requires continued access to specialized testing for Measurable Residual Disease (MRD) detection in hematologic malignancies. MRD is a powerful diagnostic and prognostic tool that quantifies the presence of residual cancer cells during and after treatment in patients with multiple myeloma, B-cell acute lymphoblastic leukemia (B-ALL), and chronic lymphocytic leukemia (CLL).
Classifications
Documents (1)
- 36C26026Q0807_1.docx.docx14 KBNot yet available
Contacts
- Contract Specialist
Similar contracts
- New Lab Staffing Contract Fiscal Year 2027-Path & LabDue Oct 14, 2026
- NWI Offsite Pathology ServicesNebraskaDue Nov 10, 2026
- Heart Transplant Biopsies Consultation Services (Examination and Interpretation)-Light Microscopy, Immunofluorescence, and Electron Microscopy-Salt Lake City VA Health Care SystemUTDue Oct 16, 2026
- FY27 Mobile PET/CT ImagingFloridaDue Oct 16, 2026
- CAREDX Post heart transplant rejection surveillance testsDue Oct 12, 2026
- FY27 Mobile PET/CT ImagingFloridaDue Oct 16, 2026